Antitumor activities of an oncolytic adenovirus equipped with a double siRNA targeting Ki67 and hTERT in renal cancer cells

Virus Research

Volumn 181, Issue , 2014, Pages 61-71

  Fang, Lin ^a   Cheng, Qian ^a   Li, Wang ^a   Liu, Junjie ^a   Li, Liantao ^a   Xu, Kai ^a   Zheng, Junnian ^a  

^a XUZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Human telomerase reverse transcriptase; Ki67; Renal cell carcinoma (RCC); RNA interference

Indexed keywords

HUMAN TELOMERASE REVERSE TRANSCRIPTASE; KI67; RENAL CELL CARCINOMA (RCC); RNA INTERFERENCE;

ADENOVIRIDAE; ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOPATHOGENIC EFFECT, VIRAL; DISEASE MODELS, ANIMAL; GENE EXPRESSION; GENE ORDER; GENETIC THERAPY; GENETIC VECTORS; HUMANS; KI-67 ANTIGEN; KIDNEY NEOPLASMS; MALE; MICE; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; PROMOTER REGIONS, GENETIC; RNA, SMALL INTERFERING; TELOMERASE; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84893823652     PISSN: 01681702     EISSN: 18727492     Source Type: Journal    
DOI: 10.1016/j.virusres.2013.12.021     Document Type: Article

References (27)

1. Agrawal A., Dang S., Gabrani R. Recent patents on anti-telomerase cancer therapy. Recent Pat. Anticancer Drug Discov. 2012, 7(1):102-117.
2. Balleine R.L., Webster L.R., Davis S., Salisbury E.L., Palazzo J.P., Schwartz G.F., Cornfield D.B., Walker R.L., Byth K., Clarke C.L., Meltzer P.S. Molecular grading of ductal carcinoma in situ of the breast. Clin. Cancer Res. 2008, 14(24):8244-8252.
3. Bauerschmitz G.J., Guse K., Kanerva A., Menzel A., Herrmann I., Desmond R.A., Yamamoto M., Nettelbeck D.M., Hakkarainen T., Dall P., Curiel D.T., Hemminki A. Triple-targeted oncolytic adenoviruses featuring the cox2 promoter, E1A transcomplementation, and serotype chimerism for enhanced selectivity for ovarian cancer cells. Mol. Ther. 2006, 14(2):164-174.
4. Bertucci F., Finetti P., Roche H., Le Doussal J.M., Marisa L., Martin A.L., Lacroix-Triki M., Blanc-Fournier C., Jacquemier J., Peyro-Saint-Paul H., Viens P., Sotiriou C., Birnbaum D., Penault-Llorca F. Comparison of the prognostic value of genomic grade index Ki67 expression and mitotic activity index in early node-positive breast cancer patients. Ann. Oncol. 2013, 24(3):625-632.
5. Cascallo M. The use of oncolytic adenovirus for the treatment of cancer. Methods Find. Exp. Clin. Pharmacol. 2010, 32(Suppl. A):3-7.
6. Cerullo V., Vaha-Koskela M., Hemminki A. Oncolytic adenoviruses: a potent form of tumor immunovirotherapy. Oncoimmunology 2012, 1(6):979-981.
7. Doloff J.C., Jounaidi Y., Waxman D.J. Dual E1A oncolytic adenovirus: targeting tumor heterogeneity with two independent cancer-specific promoter elements, DF3/MUC1 and hTERT. Cancer Gene Ther. 2011, 18(3):153-166.
8. Ellebaek E., Engell-Noerregaard L., Iversen T.Z., Froesig T.M., Munir S., Hadrup S.R., Andersen M.H., Svane I.M. Metastatic melanoma patients treated with dendritic cell vaccination, Interleukin-2 and metronomic cyclophosphamide: results from a phase II trial. Cancer Immunol. Immunother. 2012, 61(10):1791-1804.
9. Fung A.S., Jonkman J., Tannock I.F. Quantitative immunohistochemistry for evaluating the distribution of Ki67 and other biomarkers in tumor sections and use of the method to study repopulation in xenografts after treatment with paclitaxel. Neoplasia 2012, 14(4):324-334.
10. Galanis E. Therapeutic potential of oncolytic measles virus: promises and challenges. Clin. Pharmacol. Ther. 2010, 88(5):620-625.
11. Hallden G., Portella G. Oncolytic virotherapy with modified adenoviruses and novel therapeutic targets. Expert Opin. Ther. Targets 2012, 16(10):945-958.
12. Herlin P. How to evaluate Ki67. Ann. Pathol. 2011, 31(5 Suppl.):S49-S51.
13. Iatropoulos M.J., Williams G.M. Proliferation markers. Exp. Toxicol. Pathol. 1996, 48(2-3):175-181.
14. Kausch I., Jiang H., Brocks C., Albers A., Kruger S., Sczakiel G., Jocham D. Ki-67 antisense therapy in murine renal cell carcinoma models. Aktuelle Urol. 2005, 36(2):142-148.
15. Kim S.M., Lee K.N., Lee S.J., Ko Y.J., Lee H.S., Kweon C.H., Kim H.S., Park J.H. Multiple shRNAs driven by U6 and CMV promoter enhances efficiency of antiviral effects against foot-and-mouth disease virus. Antiviral Res. 2010, 87(3):307-317.
16. Kirkpatrick K.L., Mokbel K. The significance of human telomerase reverse transcriptase (hTERT) in cancer. Eur. J. Surg. Oncol. 2001, 27(8):754-760.
17. Kruck S., Bedke J., Kuczyk M.A., Merseburger A.S. Second-line systemic therapy for the treatment of metastatic renal cell cancer. Expert Rev. Anticancer Ther. 2012, 12(6):777-785.
18. Liu J., Fang L., Cheng Q., Li L., Su C., Zhang B., Pei D., Yang J., Li W., Zheng J. Effects of G250 promoter controlled conditionally replicative adenovirus expressing Ki67-siRNA on renal cancer cell. Cancer Sci. 2012, 103(10):1880-1888.
19. Mertani H.C., Belin S., Diaz J.J. Ki67, nucleolus and cancer. Ann. Pathol. 2011, 31(5 Suppl.):S46-S48.
20. Moch H. An overview of renal cell cancer: pathology and genetics. Semin. Cancer Biol. 2013, 23(1):3-9.
21. Ramachandran P.V., Ignacimuthu S. RNA interference as a plausible anticancer therapeutic tool. Asian Pac. J. Cancer Prev. 2012, 13(6):2445-2452.
22. Rodriguez-Alonso A., Pita-Fernandez S., Gonzalez-Carrero J., Nogueira-March J.L. p53 and ki67 expression as prognostic factors for cancer-related survival in stage T1 transitional cell bladder carcinoma. Eur. Urol. 2002, 41(2):182-188. (discussion 188-9).
23. Tan P.H., Bay B.H., Yip G., Selvarajan S., Tan P., Wu J., Lee C.H., Li K.B. Immunohistochemical detection of Ki67 in breast cancer correlates with transcriptional regulation of genes related to apoptosis and cell death. Mod. Pathol. 2005, 18(3):374-381.
24. Ugai H., Murata T., Nagamura Y., Ugawa Y., Suzuki E., Nakata H., Kujime Y., Inamoto S., Hirose M., Inabe K., Terashima M., Yamasaki T., Liu B., Nakade K., Pan J., Kimura M., Saito I., Hamada H., Obata Y., Yokoyama K.K. A database of recombinant viruses and recombinant viral vectors available from the RIKEN DNA bank. J. Gene Med. 2005, 7(9):1148-1157.
25. Wang M.B., Helliwell C.A., Wu L.M., Waterhouse P.M., Peacock W.J., Dennis E.S. Hairpin RNAs derived from RNA polymerase II and polymerase III promoter-directed transgenes are processed differently in plants. RNA 2008, 14(5):903-913.
26. Zhang R.G., Zhao J.J., Yang L.Q., Yang S.M., Wang R.Q., Chen W.S., Peng G.Y., Fang D.C. RNA interference-mediated hTERT inhibition enhances TRAIL-induced apoptosis in resistant hepatocellular carcinoma cells. Oncol. Rep. 2010, 23(4):1013-1019.
27. Zheng J.N., Pei D.S., Mao L.J., Liu X.Y., Mei D.D., Zhang B.F., Shi Z., Wen R.M., Sun X.Q. Inhibition of renal cancer cell growth in vitro and in vivo with oncolytic adenovirus armed short hairpin RNA targeting Ki-67 encoding mRNA. Cancer Gene Ther. 2009, 16(1):20-32.